| Ytd | 130.37% | |
| 1y | 108.72% |
| Open | 3.07 | Prev Close | 3.08 | Low | 2.99 | High | 3.18 | Mkt Cap | 294.43M |
| Vol | 1.26M | Avg Vol | 1.23M | EPS | -1.96 | P/E | N/A | Forward P/E | -0.89 |
| Beta | 1.74 | Short Ratio | 3.17 | Inst. Own | 98.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-10 | 50-d Avg | 4.19 | 200-d Avg | 3.34 | 1yr Est | 9.50 |
ZNTL News
Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) received a bullish initiation from William Blair on Tues
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead
William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) wi
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Confe
BlackRock Inc. acquired a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) during the s
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin
Zentalis Pharmaceuticals, Inc. earns a cautious Buy rating, driven by azenosertib's potential in Cyc
Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zental
Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zental
Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session
All of the securities to be sold in the proposed offering will be sold by the Company. The Company a
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zental
Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DE
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clini
Rodman & Renshaw initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy ratin
Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian
Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenoser
US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big ga
Mizuho analyst Graig Suvannavejh initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) wit
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clini
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinic
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the comb
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinic
400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk
Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy
U.S. stocks mixed, Nasdaq up 100 points. Inflation rate surges to 3.3%. Japan's Nikkei 225 and C
Dow Jones fell 100 points as Sun Pharma offered 12 billion to buy Organon, Organon shares jumped 26.
U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big
On Friday, 497 companies set new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
On Friday, 431 companies hit new 52-week lows.
On Thursday, 236 companies hit new 52-week lows.